Repligen (NASDAQ:RGEN) Shares Down 6.7% on Insider Selling

Repligen Corporation (NASDAQ:RGEN) shares dropped 6.7% during mid-day trading on Monday following insider selling activity. The company traded as low as $136.61 and last traded at $137.1350. Approximately 771,221 shares changed hands during trading, a decline of 21% from the average daily volume of 980,143 shares. The stock had previously closed at $147.01.

Specifically, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Analysts Set New Price Targets

Several research firms recently issued reports on RGEN. Wolfe Research initiated coverage on shares of Repligen in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price target for the company. JPMorgan Chase & Co. lowered their price objective on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Royal Bank Of Canada began coverage on shares of Repligen in a research note on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price objective on the stock. Barclays lifted their price objective on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Finally, HSBC decreased their target price on shares of Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $164.64.

Repligen Trading Down 6.7%

The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. The firm has a market capitalization of $7.73 billion, a P/E ratio of 152.30, a PEG ratio of 2.83 and a beta of 1.09. The firm has a 50 day simple moving average of $122.84 and a two-hundred day simple moving average of $135.36.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. The firm had revenue of $194.25 million during the quarter, compared to analyst estimates of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business’s revenue was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities research analysts forecast that Repligen Corporation will post 1.99 earnings per share for the current year.

Hedge Funds Weigh In On Repligen

Hedge funds have recently modified their holdings of the company. Bayforest Capital Ltd bought a new position in shares of Repligen in the fourth quarter valued at approximately $32,000. Rachor Investment Advisory Services LLC bought a new stake in Repligen during the fourth quarter worth $33,000. Measured Wealth Private Client Group LLC purchased a new position in Repligen in the third quarter worth $29,000. Los Angeles Capital Management LLC purchased a new position in Repligen in the fourth quarter worth $36,000. Finally, Farther Finance Advisors LLC grew its stake in Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 128 shares during the period. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.